In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Real-world benefit seen with addition of bevacizumab to first-line chemotherapy for patients with high‐risk prognostic factors.

Outlook Therapeutics, Inc.’s OTLK share price has dipped by 6.40%, which has investors questioning if this is right time to ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Dr. Davide Soldato (Host), Dr. Harriet Kluger (Guest) Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025.